Raphael Catane

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar et al. · Annals of Oncology · 2004 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.

Alberto Gabizón, Raphael Catane, Beatrice Uziely et al. · PubMed · 1994 · 1.4K citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

Michal J. Besser, Ronnie Shapira‐Frommer, Avraham J. Treves et al. · Clinical Cancer Research · 2010 · 460 citations

Medicine, Immunology, Oncology +17

Population-based screening for breast and ovarian cancer risk due to <i>BRCA1</i> and <i>BRCA2</i>

Efrat Gabai-Kapara, Amnon Lahad, Bella Kaufman et al. · Proceedings of the National Academy of Sciences · 2014 · 345 citations · Full text

Medicine, Genetics, Oncology +17

Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.

Ephrat Levy‐Lahad, Raphael Catane, Shlomit Eisenberg et al. · PubMed · 1997 · 322 citations

Life Sciences, Genetics, Oncology +14